Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
641-660 of 2,120 trials

Placental Vascularization Study: Contrast Ultrasound

We are examining how contrast-enhanced ultrasound can help assess blood flow in the placenta for patients undergoing medical termination of pregnancy. This study compares cases of fetal growth restriction with those without to better understand placental health.

Fetal Growth RestrictionConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Nerve Damage from Cancer: New Immunotherapy Approach

We are studying a combination of treatments for patients with anti-Hu-associated nerve damage due to cancer. The goal is to see if this early immunotherapy improves symptoms and helps patients live longer without cancer progression.

Paraneoplastic Neurological Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Coronary Artery Disease: SYN2 PET Scan Study

We are testing a new tracer for PET scans to see if it helps diagnose coronary artery disease in patients who may have it. The study will also assess the safety of this new diagnostic method.

Coronary Artery Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCardiology

Non-Hodgkin Lymphoma: IPH6501 Treatment Study

We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.

Refractory Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Influenza Vaccine Study for Adults Aged 65-79

We are comparing a high-dose flu vaccine to a standard-dose vaccine to see which one better reduces hospital visits for flu and pneumonia in older adults. This study aims to improve vaccine effectiveness for this age group.

Prevention of Influenza Infection in Older AdultsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Triple-Negative Breast Cancer: Keytruda with Chemotherapy

We are studying how different chemotherapy regimens combined with Keytruda affect the immune response in patients with early-stage triple-negative breast cancer. The goal is to find the most effective treatment approach for this specific cancer type.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ovarian Stimulation in Older Women: INOVEE Study

We are comparing two doses of a fertility medication to see which produces more healthy embryos in older women undergoing fertility treatment. This study aims to improve outcomes for women trying to conceive.

Female Infertility3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Viral Lung Infection: Tozorakimab Study

We are testing the new medication tozorakimab in patients hospitalized for viral lung infections requiring oxygen. The goal is to see if it can help prevent serious complications compared to a placebo.

Acute Respiratory FailureSevere Viral Lung Infections≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Cirrhosis Treatment: Albumin and Enoxaparin Study

We are testing a new combination therapy of albumin and enoxaparin for patients with decompensated cirrhosis at high risk of complications. The study aims to assess safety and explore how this treatment may affect the disease.

Cirrhosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Pain Management in Laparoscopic Colorectal Surgery: Comparing Two Techniques

We are studying the effectiveness of two pain relief methods after laparoscopic colorectal surgery. Our goal is to find out which method reduces opioid use and improves recovery.

Patients Scheduled for Laparoscopic Colorectal Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

MECP2 Duplication Syndrome: ION440 Treatment Study

We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.

MECP2 Duplication SyndromeSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematology